GRAIL (GRAL) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $28.7 million, a 38% increase year-over-year, driven by a 52% rise in Galleri sales and strong commercial uptake, with over 250,000 tests prescribed since launch.

• Net loss for Q3 2024 was $125.7 million, an 86% improvement compared to Q3 2023, reflecting cost management and restructuring.

• The company completed a spin-off from Illumina in June 2024, becoming an independent public entity listed on NASDAQ.

• A restructuring plan in Q3 2024 reduced headcount by 30%, focused resources on Galleri, and extended the cash runway into 2028.

• The company is preparing to launch a more automated Galleri test by year-end to support scalability and cost reduction.

Financial highlights

• Screening revenue for Q3 was $25.4 million, up 52% year-over-year, with 32,600 tests sold in the quarter.

• Adjusted gross profit for Q3 was $11.8 million, up 68% year-over-year, with a margin of 41% of revenue.

• Adjusted EBITDA for Q3 was negative $108.2 million, a 14% improvement year-over-year.

• Cash and cash equivalents as of September 30, 2024, were $853.6 million.

• Net loss per share was $(3.94), compared to $(28.71) in the prior year quarter.

Outlook and guidance

• Galleri sales growth for 2024 is guided to 40–50% year-over-year.

• Cash runway is projected into 2028, with full-year 2025 cash burn expected to be approximately $325 million.

• FDA PMA submission for Galleri is planned for the first half of 2026, with potential approval in the first half of 2027.

• Anticipated results from Pathfinder II study in H2 2025 and NHS-Galleri study in 2026.

• The restructuring plan is expected to reduce annual operating expenses by $120 million, with $27 million in net savings in 2024.